

Xiao-Yuan Chu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6184487/publications.pdf>

Version: 2024-02-01

59
papers

1,988
citations

218677

26
h-index

265206

42
g-index

63
all docs

63
docs citations

63
times ranked

2960
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 756-763.	1.9	144
2	New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. <i>Molecular Cancer</i> , 2018, 17, 22.	19.2	123
3	A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells. <i>Nature Communications</i> , 2016, 7, 12692.	12.8	91
4	Targeting KDM1A attenuates Wnt/ β -catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. <i>Cancer Letters</i> , 2017, 398, 12-21.	7.2	84
5	PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. <i>Cell Death and Disease</i> , 2018, 9, 312.	6.3	81
6	Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. <i>Oncotarget</i> , 2016, 7, 62474-62489.	1.8	78
7	FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. <i>Acta Histochemica</i> , 2012, 114, 755-762.	1.8	77
8	Long non-coding RNA ROR promotes radioresistance in hepatocellular carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression. <i>Archives of Biochemistry and Biophysics</i> , 2018, 645, 117-125.	3.0	71
9	Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. <i>Oncotarget</i> , 2017, 8, 33144-33158.	1.8	66
10	Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. <i>Cancer Medicine</i> , 2017, 6, 1424-1436.	2.8	61
11	Lysine methylation of transcription factors in cancer. <i>Cell Death and Disease</i> , 2019, 10, 290.	6.3	61
12	Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 161.	8.6	54
13	TFAP2C-Activated MALAT1 Modulates the Chemoresistance of Docetaxel-Resistant Lung Adenocarcinoma Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 14, 567-582.	5.1	54
14	Wnt signaling induces radioresistance through upregulating HMGB1 in esophageal squamous cell carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 433.	6.3	53
15	FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. <i>Oncotarget</i> , 2017, 8, 8574-8589.	1.8	53
16	MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. <i>Oncotarget</i> , 2017, 8, 60624-60639.	1.8	48
17	Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 520-528.	1.7	45
18	Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance. <i>Human Cell</i> , 2021, 34, 1800-1811.	2.7	44

#	ARTICLE	IF	CITATIONS
19	Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma. <i>Experimental and Molecular Medicine</i> , 2017, 49, e293-e293.	7.7	43
20	FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 576-588.	5.1	41
21	Oncolytic Adenovirusâ€”A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. <i>Frontiers in Oncology</i> , 2019, 9, 1182.	2.8	34
22	Recent progress in the emerging role of exosome in hepatocellular carcinoma. <i>Cell Proliferation</i> , 2019, 52, e12541.	5.3	34
23	Genome-Wide Screen of DNA Methylation Changes Induced by Low Dose X-Ray Radiation in Mice. <i>PLoS ONE</i> , 2014, 9, e90804.	2.5	33
24	MAFB Promotes Cancer Stemness and Tumorigenesis in Osteosarcoma through a Sox9-Mediated Positive Feedback Loop. <i>Cancer Research</i> , 2020, 80, 2472-2483.	0.9	33
25	Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 36787-36799.	1.8	29
26	MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers. <i>Oncotarget</i> , 2017, 8, 12433-12450.	1.8	28
27	Delivery of Anti-miRNA-221 for Colorectal Carcinoma Therapy Using Modified Cord Blood Mesenchymal Stem Cells-Derived Exosomes. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 743013.	3.5	24
28	Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells. <i>Science Advances</i> , 2021, 7, .	10.3	21
29	Dysregulation of miR-6868-5p/FOXM1 circuit contributes to colorectal cancer angiogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 292.	8.6	20
30	The functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancer. <i>Life Sciences</i> , 2020, 261, 118362.	4.3	20
31	Impact on survival of the number of lymph nodes resected in patients with lymph node-negative gastric cancer. <i>World Journal of Surgical Oncology</i> , 2015, 13, 192.	1.9	19
32	The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 674919.	3.7	19
33	Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1156.	2.8	18
34	Chemotherapy is associated with increased survival from colorectal signet ring cell carcinoma with distant metastasis: A Surveillance, Epidemiology, and End Results database analysis. <i>Cancer Medicine</i> , 2019, 8, 1930-1940.	2.8	18
35	Regulation and functions of MicroRNA-49 in human cancers. <i>Cell Proliferation</i> , 2018, 51, e12465.	5.3	17
36	Expression of chemokine receptor CXCR7 in colorectal carcinoma and its prognostic significance. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13051-8.	0.5	17

#	ARTICLE	IF	CITATIONS
37	Clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma and nonmucinous adenocarcinoma: a surveillance, epidemiology, and end results (SEER) population-based study. <i>Annals of Translational Medicine</i> , 2020, 8, 205-205.	1.7	16
38	Alternative splicing of mRNA in colorectal cancer: new strategies for tumor diagnosis and treatment. <i>Cell Death and Disease</i> , 2021, 12, 752.	6.3	16
39	Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression. <i>Cell Death and Disease</i> , 2021, 12, 1047.	6.3	13
40	The Potential Roles of Exosomal Non-Coding RNAs in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 790916.	2.8	13
41	Lymph node status and its impact on the prognosis of left-sided and right-sided colon cancer: A SEER population-based study. <i>Cancer Medicine</i> , 2021, 10, 8708-8719.	2.8	12
42	PHF5A promotes colorectal cancer progression by alternative splicing of TEAD2. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1215-1227.	5.1	11
43	The role of Aurora-A in human cancers and future therapeutics. <i>American Journal of Cancer Research</i> , 2020, 10, 2705-2729.	1.4	11
44	miRNA-885-3p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora γ . <i>Oncology Reports</i> , 2018, 41, 1218-1230.	2.6	10
45	Activation of CD3 ⁺ T cells by <i>Helicobacter pylori</i> DNA vaccines in potential immunotherapy of gastric carcinoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 866-876.	3.4	9
46	The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 927.	2.8	9
47	Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 659987.	2.8	9
48	Effectiveness of TKI Inhibitors Combined With PD-1 in Patients With Postoperative Early Recurrence of HCC: A Real-World Study. <i>Frontiers in Oncology</i> , 2022, 12, 833884.	2.8	9
49	Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636913.	3.7	7
50	Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 595781.	2.8	7
51	Role of the zinc finger and SCAN domain-containing transcription factors in cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 816-836.	1.4	7
52	Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 670838.	2.8	6
53	CRISPR screen in cancer: status quo and future perspectives. <i>American Journal of Cancer Research</i> , 2021, 11, 1031-1050.	1.4	4
54	Risk of Second Primary Malignancies Based on the Histological Subtypes of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 650937.	2.8	3

#	ARTICLE	IF	CITATIONS
55	SiRNA-mediated survivin inhibition enhances chemo- or radiosensitivity of colorectal cancer cells in tumor-bearing nude mice. <i>Hepato-Gastroenterology</i> , 2010, 57, 1445-52.	0.5	3
56	Rare Gingival Metastasis by Hepatocellular Carcinoma. <i>Case Reports in Medicine</i> , 2017, 2017, 1-6.	0.7	2
57	Non-coding RNAs: emerging regulators of glucose metabolism in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 4066-4084.	1.4	2
58	A narrative review of the roles of muscle segment homeobox transcription factor family in cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 810-810.	1.7	1
59	Regional hyperthermia combined with intrapleural chemotherapy in patients with malignant pleural effusion. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 360-365.	0.1	0